Abstract
The hypofunction hypothesis of glutamatergic neurotransmission via N-methyl-D-aspartate (NMDA) receptors in the pathophysiology of schizophrenia suggests that increasing NMDA receptor function via pharmacological manipulation could provide a new therapeutic strategy for schizophrenia. The glycine modulatory site on NMDA receptor complex is the one of the most attractive therapeutic targets for schizophrenia. One means of enhancing NMDA receptor neurotransmission is to increase the availability of the obligatory co-agonist glycine at modulatory site on the NMDA receptors through the inhibition of glycine transporter-1 (GlyT-1) on glial cells. Some clinical studies have demonstrated that the GlyT-1 inhibitor sarcosine (N-methylglycine) shows antipsychotic activity in patients with schizophrenia. Currently, a number of pharmaceutical companies have been developing novel and selective GlyT-1 inhibitors for the treatment of schizophrenia. A recent double blind phase II study demonstrated that the novel GlyT-1 inhibitor RG1678 has a robust and clinically meaningful effect in patients with schizophrenia. In this article, the author reviews the recent findings on the GlyT-1 as a potential therapeutic target of schizophrenia.
Keywords: Schizophrenia, NMDA receptor, Glutamate, Glycine, Transporter, Glia
Current Pharmaceutical Design
Title: Glycine Transporter-1: A New Potential Therapeutic Target for Schizophrenia
Volume: 17 Issue: 2
Author(s): Kenji Hashimoto
Affiliation:
Keywords: Schizophrenia, NMDA receptor, Glutamate, Glycine, Transporter, Glia
Abstract: The hypofunction hypothesis of glutamatergic neurotransmission via N-methyl-D-aspartate (NMDA) receptors in the pathophysiology of schizophrenia suggests that increasing NMDA receptor function via pharmacological manipulation could provide a new therapeutic strategy for schizophrenia. The glycine modulatory site on NMDA receptor complex is the one of the most attractive therapeutic targets for schizophrenia. One means of enhancing NMDA receptor neurotransmission is to increase the availability of the obligatory co-agonist glycine at modulatory site on the NMDA receptors through the inhibition of glycine transporter-1 (GlyT-1) on glial cells. Some clinical studies have demonstrated that the GlyT-1 inhibitor sarcosine (N-methylglycine) shows antipsychotic activity in patients with schizophrenia. Currently, a number of pharmaceutical companies have been developing novel and selective GlyT-1 inhibitors for the treatment of schizophrenia. A recent double blind phase II study demonstrated that the novel GlyT-1 inhibitor RG1678 has a robust and clinically meaningful effect in patients with schizophrenia. In this article, the author reviews the recent findings on the GlyT-1 as a potential therapeutic target of schizophrenia.
Export Options
About this article
Cite this article as:
Hashimoto Kenji, Glycine Transporter-1: A New Potential Therapeutic Target for Schizophrenia, Current Pharmaceutical Design 2011; 17 (2) . https://dx.doi.org/10.2174/138161211795049598
DOI https://dx.doi.org/10.2174/138161211795049598 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Akt in Prostate Cancer: Possible Role in Androgen-Independence
Current Drug Metabolism Emerging Molecular Targets for Imaging of Atherosclerotic Plaque using Positron Emission Tomography
Current Radiopharmaceuticals General Aspects of Metal Toxicity
Current Medicinal Chemistry Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery A Preliminary Assessment of the Structure-Activity Relationship of Benzimidazole-Based Anti-Proliferative Agents
Letters in Drug Design & Discovery Integrative Approaches for microRNA Target Prediction: Combining Sequence Information and the Paired mRNA and miRNA Expression Profiles
Current Bioinformatics Structure-Function Based Design of Small Molecule Inhibitors Targeting Rho Family GTPases
Current Topics in Medicinal Chemistry The Importance of Selenium Biofortification in Food Crops
Current Nutrition & Food Science The Pim Kinases: New Targets for Drug Development
Current Drug Targets Nature Against Depression
Current Medicinal Chemistry HER-2 Signaling and Inhibition in Breast Cancer
Current Cancer Drug Targets Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Privileged Structures: Applications in Drug Discovery
Combinatorial Chemistry & High Throughput Screening Targeting Oncogenes and Tumor Suppressors genes to Mitigate Chemoresistance
Current Cancer Drug Targets Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics Environmental Chemicals and Breast Cancer Risk – A Structural Chemistry Perspective
Current Medicinal Chemistry Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Chemopreventive Effects of Conjugated Linolenic Acids (CLN) Occurring in Plant Seed Oils
Current Nutrition & Food Science Antitumor Effects of Celastrol and Semi-Synthetic Derivatives
Mini-Reviews in Organic Chemistry